Aardvark Therapeutics, Inc. Common Stock (AARD) - Total Assets
Based on the latest financial reports, Aardvark Therapeutics, Inc. Common Stock (AARD) holds total assets worth $133.23 Million USD as of September 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. See AARD equity financing ratio to measure how much of total assets are equity-financed.
Aardvark Therapeutics, Inc. Common Stock - Total Assets Trend (2022–2024)
This chart illustrates how Aardvark Therapeutics, Inc. Common Stock's total assets have evolved over time, based on quarterly financial data. Check Aardvark Therapeutics, Inc. Common Stock tangible net worth ratio to evaluate the tangible quality of the company's equity base.
Aardvark Therapeutics, Inc. Common Stock - Asset Composition Analysis
Current Asset Composition (December 2024)
Aardvark Therapeutics, Inc. Common Stock's total assets of $133.23 Million consist of 95.7% current assets and 4.4% non-current assets.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 79.5% |
| Accounts Receivable | $0.00 | 0.0% |
| Inventory | $0.00 | 0.0% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $0.00 | 0.0% |
| Goodwill | $0.00 | 0.0% |
Asset Composition Trend (2022–2024)
This chart illustrates how Aardvark Therapeutics, Inc. Common Stock's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. For live market cap, price, and company overview, see how much is Aardvark Therapeutics, Inc. Common Stock worth.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Aardvark Therapeutics, Inc. Common Stock's current assets represent 95.7% of total assets in 2024, a decrease from 98.4% in 2022.
- Cash Position: Cash and equivalents constituted 79.5% of total assets in 2024, down from 92.9% in 2022.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, unchanged from 0.0% in 2022.
- Asset Diversification: The largest asset category is goodwill at 0.0% of total assets.
Aardvark Therapeutics, Inc. Common Stock Competitors by Total Assets
Key competitors of Aardvark Therapeutics, Inc. Common Stock based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Biomarin Pharmaceutical Inc
NASDAQ:BMRN
|
USA | $8.59 Billion |
|
Cyclacel Pharmaceuticals Inc
NASDAQ:CYCC
|
USA | $4.40K |
|
Krystal Biotech Inc
NASDAQ:KRYS
|
USA | $1.40 Billion |
|
Verona Pharma PLC ADR
NASDAQ:VRNA
|
USA | $572.87 Million |
|
Centessa Pharmaceuticals PLC ADR
NASDAQ:CNTA
|
USA | $641.76 Million |
|
Beijing Tiantan Biological Products Corp Ltd
SHG:600161
|
China | CN¥16.55 Billion |
|
Hebei Changshan Biochem Pharma
SHE:300255
|
China | CN¥4.66 Billion |
|
BB Biotech AG
SW:BION
|
Switzerland | CHF2.64 Billion |
Aardvark Therapeutics, Inc. Common Stock - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 12.03 | 31.65 | 7.50 |
| Quick Ratio | 12.03 | 31.65 | 7.50 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $118.47 Million | $80.05 Million | $8.99 Million |
Aardvark Therapeutics, Inc. Common Stock - Advanced Valuation Insights
This section examines the relationship between Aardvark Therapeutics, Inc. Common Stock's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 2.16 |
| Latest Market Cap to Assets Ratio | 1.07 |
| Asset Growth Rate (YoY) | 635.6% |
| Total Assets | $77.51 Million |
| Market Capitalization | $83.17 Million USD |
Valuation Analysis
Above Book Valuation: The market values Aardvark Therapeutics, Inc. Common Stock's assets above their book value (1.07x), reflecting positive investor sentiment about the company's future prospects.
Rapid Asset Growth: Aardvark Therapeutics, Inc. Common Stock's assets grew by 635.6% over the past year, indicating significant expansion of the company's resource base.
Annual Total Assets for Aardvark Therapeutics, Inc. Common Stock (2022–2024)
The table below shows the annual total assets of Aardvark Therapeutics, Inc. Common Stock from 2022 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-12-31 | $77.51 Million | +635.64% |
| 2023-12-31 | $10.54 Million | -37.12% |
| 2022-12-31 | $16.76 Million | -- |
About Aardvark Therapeutics, Inc. Common Stock
Aardvark Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing small-molecule therapeutics to activate innate homeostatic pathways for the treatment of metabolic diseases. Its lead product candidate is ARD-101, an oral gut-restricted small-molecule agonist of certain targeting bitter taste receptors expressed in the gut lumen, which is in the Phase 3 clinical trial… Read more